Apr 12 |
NeuroBo Pharmaceuticals files for $150M mixed shelf
|
Apr 1 |
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
|
Mar 28 |
NeuroBo Pharmaceuticals GAAP EPS of -$2.46
|
Mar 28 |
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
|
Mar 13 |
NeuroBo Phase 2a study for MASH drug to proceed as planned
|
Mar 13 |
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
|
Mar 4 |
NeuroBo Pharmaceuticals appoints Marshall Woodworth as CFO
|
Mar 4 |
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
|
Feb 29 |
NeuroBo stock jumps 14% on weight-loss drug update
|
Feb 29 |
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
|